TD Cowen raised the firm’s price target on Quanterix (QTRX) to $16 from $13.50 and keeps a Hold rating on the shares. The firm said Q3 results beat with sales and its Alzheimer’s blood testing sales are nascent, though drivers are coming into place for traction in 2025 and beyond.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX: